TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP-025 capsules
Description: FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-025 capsules
Description: FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FP-025 capsules
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FP-025 capsules
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study: NCT02038790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone Sublingual Film
Description: A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Study: NCT02111915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THPP-P
Description: Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
Study: NCT02038790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zubsolv sublingual tablets
Description: A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Study: NCT03649386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated and humidified breathing circuit on
Description: Heated and humidified breathing circuit will be turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated and humidified breathing circuit off
Description: Heated and humidified breathing circuit will be turned off.
Study: NCT01512329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pacing
Description: 3 one-on-one sessions weekly for 3 consecutive weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 3 one-on-one sessions weekly for 3 consecutive weeks
Study: NCT06330766

Intervention type: PROCEDURE
Intervention: No preoperative dental screening
Description: Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
Study: NCT02071329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine FP-01.1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Virus Challenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virus Challenge
Study: NCT02725749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXE
Description: Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser + EXE
Description: Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks.
Study: NCT03371589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution for otic injection
Study: NCT03364062

Intervention type: PROCEDURE
Intervention: cemented shoulder replacement
Description: proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
Study: NCT02296229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: up to 9 months at the discretion of the treating physician
Study: NCT01003067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh implementation
Description: Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
Study: NCT04574674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility exercise programme
Description: Static passive flexibility exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise programme
Description: Body weight and resistance bands exercises.
Study: NCT02174809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of 5As to discuss gestational weight gain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT00610714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous infusion
Study: NCT03973567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants
Description: On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
Study: NCT04019197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: semaglutide subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection
Study: NCT02057276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Occupational Therapy
Study: NCT02837055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight intubation
Description: patients are intubated with an endotracheal tube with an integrated camera

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional intubation
Description: patients are intubated with a conventional endotracheal tube
Study: NCT02244125

Intervention type: DRUG
Group type: OTHER
Intervention: PCD
Description: STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]

Intervention type: DRUG
Group type: OTHER
Intervention: PCD
Description: STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous transplantation (ASCT)
Description: Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation
Study: NCT02869451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: Prescribed one week prior to quit and continued until the 6 month follow-up visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Initiated at smoking quit date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: Initiated at smoking quit date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling for marijuana and smoking cessation
Description: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management
Description: treatment that provides money rewards for abstinence from smoking and marijuana
Study: NCT03908463

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: All coronary intervention procedures will be performed according to current standard techniques.
Study: NCT04437602

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography (CEM)
Description: Additional CEM in preoperative staging
Study: NCT03628391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for ICU delirium, titrated on validated screening tool-based diagnosis
Study: NCT04367649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: * Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic restorative treatment
Description: Caries removal using excavators, then restoration using glass ionomer (GIC)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional restorative treatment
Description: Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
Study: NCT02094664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated and humidified oxygen
Study: NCT02111915

Intervention type: OTHER
Group type: OTHER
Intervention: EUC
Description: EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EUC
Description: EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
Study: NCT03043690

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ammonium succinate
Description: 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.

Intervention type: OTHER
Intervention: Placebo
Description: 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
Study: NCT03178825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Consecutive and coincident fractional 2940 nm and 1470 nm lasers
Study: NCT00302172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted.
Study: NCT04556591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention (JITAI)
Description: JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
Study: NCT00510107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 120 mg/m2 will be given on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 will be given on day 1.
Study: NCT02591836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene
Study: NCT06187558

Intervention type: PROCEDURE
Intervention: Pelvic and abdominal organ suspension technique
Description: The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
Study: NCT03533023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating + Standard of Care
Description: Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
Study: NCT02389361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaldiar
Description: Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
Study: NCT02941484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: jejunostomy tube feeding (JTF)
Description: The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
Study: NCT02955407

Intervention type: OTHER
Intervention: no intervention
Description: observational case-control study

Intervention type: OTHER
Intervention: no intervention
Description: observational case-control study
Study: NCT02591836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene
Study: NCT02389361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol-Tramadol
Description: Postoperative analgesia with intravenous Paracetamol and Tramadol
Study: NCT02933047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total laparoscopic hysterectomy
Study: NCT03627247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management
Description: Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
Study: NCT05907512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).